Cabozantinib With Topotecan-Cyclophosphamide
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT04661852 |
Recruitment Status :
Completed
First Posted : December 10, 2020
Last Update Posted : February 15, 2023
|
Sponsor:
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Steven DuBois, MD, Dana-Farber Cancer Institute
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
Recruitment Status : | Completed |
---|---|
Actual Primary Completion Date : | October 24, 2022 |
Actual Study Completion Date : | October 24, 2022 |